We are international
Donate
• about myeloma TEXT SIZE   
    back

Elotuzumab (formerly known as HuLuc63) is a monoclonal antibody that targets SLAMF7, a cell surface glycoprotein highly expressed on myeloma cells and hematopoietic cells but not expressed on nonhematopoietic cells . Elotuzumab is currently in clinical trials for newly diagnosed, previously untreated and relapsed or refractory myeloma.

elotuzumab

Expanded Access Treatment Protocol CA204-143
An Expanded Access Program for Elotuzumab with Lenalidomide (Revlimid®) and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov Identifier:
NCT02368301


Clinical Trial Fact Sheet for the ELOQUENT - 1 Trial
Active, Not Recruiting

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma.

The Eloquent Trial fact sheets are also available in German, French, Italian, Spanish, and Dutch.

Clinical Trial Fact Sheet for the ELOQUENT - 2 Trial
Active, Not Recruiting

Phase III Randomized, Open-label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma


Elotuzumab Open Clinical Trials
ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.